NASDAQ:SVRA Savara (SVRA) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free SVRA Stock Alerts $4.12 -0.12 (-2.83%) (As of 09:57 AM ET) Add Compare Share Share Today's Range$4.12▼$4.2150-Day Range$4.24▼$5.5952-Week Range$1.78▼$5.70Volume35,664 shsAverage Volume836,738 shsMarket Capitalization$569.18 millionP/E RatioN/ADividend YieldN/APrice Target$8.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Savara alerts: Email Address Savara MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside95.7% Upside$8.20 Price TargetShort InterestBearish5.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.70 out of 5 starsMedical Sector677th out of 907 stocksPharmaceutical Preparations Industry310th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingSavara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSavara has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.57% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Savara has recently increased by 8.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SVRA. Previous Next 2.6 News and Social Media Coverage News SentimentSavara has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Savara this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for SVRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Savara to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Savara insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.58% of the stock of Savara is held by insiders.Percentage Held by Institutions87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($0.38) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -12.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -12.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Savara Stock (NASDAQ:SVRA)Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More SVRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SVRA Stock News HeadlinesApril 20, 2024 | americanbankingnews.comJMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA)April 20, 2024 | seekingalpha.comFYBR, BCRX and SABR are among after hour moversApril 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 11, 2024 | markets.businessinsider.comOptimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study OutcomesMarch 22, 2024 | businesswire.comSavara Announces New Employment Inducement GrantMarch 13, 2024 | msn.comSavara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 TrialMarch 11, 2024 | msn.comFDA lifts partial hold on Nurix Phase 1 study for NX-2127March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with MolgramostimApril 25, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 10, 2024 | finance.yahoo.comSVRA Jul 2024 7.500 callMarch 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong FinancialsMarch 7, 2024 | msn.comSVRA Stock Earnings: Savara Beats EPS for Q4 2023March 7, 2024 | finance.yahoo.comSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | usatoday.comBest penny stocks of March 2024March 6, 2024 | finance.yahoo.comSavara to Present at the Barclays 26th Annual Global Healthcare ConferenceMarch 1, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Savara (SVRA)February 24, 2024 | msn.comSavara (SVRA) Price Target Increased by 22.98% to 7.21February 22, 2024 | au.finance.yahoo.comSavara Inc. (YB4P.F)February 21, 2024 | msn.comSee Leaked Details of Bensoul, Nviiri and Savara's Music ProjectFebruary 20, 2024 | finance.yahoo.comSavara Inc. (NASDAQ:SVRA): Are Analysts Optimistic?February 15, 2024 | msn.comJMP starts Savara at buy, cites market potential for lung disease drugFebruary 15, 2024 | benzinga.comSavara Stock (NASDAQ:SVRA) Dividends: History, Yield and DatesFebruary 6, 2024 | msn.comSavara Inc. to Participate in Prominent Healthcare Conferences, Casting Spotlight on Future PlansDecember 30, 2023 | finance.yahoo.comInsider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA)December 22, 2023 | msn.comSavara launches aPAP ClearPath blood test for rare lung diseaseDecember 21, 2023 | finance.yahoo.comSavara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)December 20, 2023 | msn.comSavara added to Nasdaq Biotechnology IndexSee More Headlines Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$8.20 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+93.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.27% Return on Assets-35.94% Debt Debt-to-Equity Ratio0.19 Current Ratio15.66 Quick Ratio15.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book4.08Miscellaneous Outstanding Shares138,150,000Free Float131,821,000Market Cap$585.76 million OptionableOptionable Beta0.77 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesRobert N. Neville (Age 51)Chairman of the Board, Chief Executive Officer Taneli Jouhikainen (Age 51)President, Chief Operating Officer David L. Lowrance (Age 50)Chief Financial Officer Nevan C. Elam (Age 49)Independent Director Richard J. Hawkins (Age 68)Independent Director Joseph S. McCracken Ph.D. (Age 64)Independent Director Matthew Pauls J.D. (Age 46)Independent Director Yuri Pikover (Age 56)Independent Director More ExecutivesKey CompetitorsAerovate TherapeuticsNASDAQ:AVTEPraxis Precision MedicinesNASDAQ:PRAXPharming GroupNASDAQ:PHARDisc MedicineNASDAQ:IRONCogent BiosciencesNASDAQ:COGTView All CompetitorsInsiders & InstitutionsSivia Capital Partners LLCBought 36,000 shares on 3/13/2024Ownership: 0.026%Wellington Management Group LLPBought 2,060,173 shares on 3/5/2024Ownership: 1.522%Superstring Capital Management LPBought 814,266 shares on 2/14/2024Ownership: 0.602%Tower Research Capital LLC TRCBought 16,959 shares on 2/13/2024Ownership: 0.014%Jump Financial LLCBought 104,174 shares on 2/7/2024Ownership: 0.101%View All Insider TransactionsView All Institutional Transactions SVRA Stock Analysis - Frequently Asked Questions Should I buy or sell Savara stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares. View SVRA analyst ratings or view top-rated stocks. What is Savara's stock price target for 2024? 5 Wall Street research analysts have issued 12 month target prices for Savara's shares. Their SVRA share price targets range from $4.00 to $16.00. On average, they predict the company's stock price to reach $8.20 in the next twelve months. This suggests a possible upside of 95.7% from the stock's current price. View analysts price targets for SVRA or view top-rated stocks among Wall Street analysts. How have SVRA shares performed in 2024? Savara's stock was trading at $4.70 at the beginning of 2024. Since then, SVRA stock has decreased by 10.9% and is now trading at $4.19. View the best growth stocks for 2024 here. When is Savara's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SVRA earnings forecast. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP). How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SVRA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry"The Biggest Drug Ever" Is ComingBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
